Streetbeat News

Products Services

CMPS

COMPASS Pathways plc (NASDAQ:CMPS) has shared results from its research on the potential of its AI technologies to support its proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression (TRD). The AI model could predict results up to 12 weeks post-treatment. The model reportedly yielded a cross-validated accuracy of 85% and 88% at the three- and twelve-week timepoints, respectively.

Portfolio Pulse from Lara Goldstein

September 06, 2023 | 8:10 pm

VLCN

Volcon ePowersports has announced that it expects to launch its Grunt Evo model in Q3 2023 and its Runt LT model in Q4 2023.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 8:05 pm

AMRX

Amneal Pharmaceuticals has received approval from the U.S. FDA for its calcium gluconate in sodium chloride injection, a product currently on the FDA shortage list. The approval received the FDA's Competitive Generic Therapy designation with 180-day exclusivity. The product is used for the treatment of acute symptomatic hypocalcemia in pediatric and adult patients. U.S. annual sales for the product were $107 million for the 12 months ended June 2023.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 8:00 pm

BSX

Boston Scientific has received FDA approval for its latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure Device. This approval could potentially boost the company's revenues and market share in the medical devices sector.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 8:00 pm

COIN

PYPL

Huobi, a Seychelles-based cryptocurrency exchange, will list PayPal's newly launched stablecoin, PYUSD, by September 7, 2023. The trading of PYUSD will commence once the deposit volume aligns with market demand. The stablecoin, issued by the Paxos Trust Company, is fully backed through U.S. dollar deposits, short-term U.S. treasury bonds, and equivalent cash reserves. Other exchanges like BitMart, Kraken, and Coinbase Global Inc have also started trading the stablecoin.

Portfolio Pulse from Khyathi Dalal

September 06, 2023 | 7:56 pm

JOBY

Joby Aviation has received FAA approval for its Certification Plans for the Energy Storage and Distribution System onboard its aircraft. This includes the batteries, high-voltage power distribution, and associated electrical wiring. The company now has more than two thirds of its Certification Plans accepted and is on track to launch commercial electric air taxi service in US cities in 2025.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 7:37 pm

VERB

Verb Technology Company, Inc. (NASDAQ:VERB) shares dropped after a surge due to the announcement of a technology integration and strategic relationship with TikTok. The collaboration is expected to benefit Verb's livestream social shopping platform, MARKET.live, by exposing it to TikTok's 150 million US users. However, the stock pulled back sharply on Wednesday on above-average volume.

Portfolio Pulse from Ryan Gustafson

September 06, 2023 | 7:26 pm

LMAT

Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ:LMAT) with an Outperform rating and a price target of $70. The company generates 90% of its sales from a third of its core markets, and its products are used by 11,000 vascular surgeons from 4,800 hospitals. LMAT's growth strategy includes smaller strategic acquisitions, with a successful track record of securing 70% of their 24 acquisition endeavors over the past 20 years.

Portfolio Pulse from Vandana Singh

September 06, 2023 | 7:04 pm

MRNA

NVAX

PFE

The FDA plans to approve updated versions of the Covid booster as early as Friday, targeting the XBB.1.5 omicron subvariant. The timeline for authorization could extend into next week. The FDA is considering granting the boosters a full approval license instead of an emergency use authorization. Pfizer and Moderna have indicated the list price for the vaccines will be $110 to $130 per dose. Novavax’s vaccine, available through emergency use authorization, will continue to be covered.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 7:02 pm

SILK

Oppenheimer has initiated coverage on Silk Road Medical Inc (NASDAQ:SILK) with an Outperform rating and a price target of $30. Silk Road Medical has pioneered the Transcarotid Artery Revascularization (TCAR) method for stroke prevention, leading to impressive revenue growth. However, a CMS proposal for equal reimbursement for TCAR and another method has led to a revision in SILK's projections. The company's shares are up 3.33% at $19.22.

Portfolio Pulse from Vandana Singh

September 06, 2023 | 6:52 pm